Cure Forward Launches Precision Medicine Engagement Platform For Cancer Patients

Multi-sided Technology Platform Developed to Make Genomic Information Usable for Consumers and Accelerate Clinical Trial Enrollment

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Cure Forward today announced the launch of its online precision medicine platform, www.cureforward.com, in public beta. The company began in private beta earlier this year, following the announcement of a $15 million round of Series A financing from New York-based Apple Tree Partners, where the company was incubated.

“Precision medicine is revolutionizing cancer treatment,“ said Cure Forward CEO Martin Naley. “Our company is built on the desire to help patients identify and better understand all possible and relevant treatment options for their condition.“”

Cure Forward is a multi-sided platform bridging the gap for patients and precision medicine, beginning in cancer. The company links the interests of patients, family caregivers, diagnostic testing laboratories, clinical trial sponsors, and health care providers.

Through Cure Forward’s website, patients can retrieve molecular diagnostic test results ordered by their physicians from accredited laboratory test providers, and then use that data to access educational information, collaborate with other patients, or investigate treatment options including clinical trials. With its unique clinical trial matching technology, Cure Forward has created a streamlined process to directly connect clinical trial administrators with participating patients. The company inverts conventional approaches to trial matching by bringing trial invitations directly to patients.

“Precision medicine is revolutionizing cancer treatment,“ said Cure Forward CEO Martin Naley. “Our company is built on the desire to help patients identify and better understand all possible and relevant treatment options for their condition.“

“By facilitating participation in clinical trials, Cure Forward has the potential to propel precision medicine forward and advance targeted treatments to the market more quickly,” said Aaron Kantoff, Vice President at Apple Tree Partners and a member of Cure Forward’s Board of Directors.

As part of private beta, Cure Forward announced key partnerships including US Oncology Research, Paradigm Diagnostics and Cynvenio Biosystems that will propel its goal of helping patients bridge the gap between initial diagnosis and precision medicine strategies. During public beta, the company will continue to build its community of patients, caregivers, and survivors, while growing its roster of innovative clinical trials recruiting through the platform.

The public beta phase is expected to last through early 2016. For more information, please visit us at www.CureForward.com.

About Cure Forward

Cure Forward is built on the desire to help patients identify and better understand relevant treatment options for their condition by bridging the gap for patients and precision medicine, beginning in cancer. Through our website, patients can become champions of their own care, work more effectively with care providers and make more informed choices toward the best treatment paths. As a multisided platform, the company overcomes inefficiencies that currently separate patients from the insights and options that can shape their care and support their treatment journey. Cure Forward solves critical business needs for its diagnostic laboratory, health care provider, and clinical trial partners, including the potential to fill trials more quickly through its unique clinical trial exchange. Cure Forward is based in Cambridge, Massachusetts and was incubated and launched by Apple Tree Partners, a leading healthcare venture capital firm headquartered in New York City.